Chengdu Easton Biopharmaceuticals Co Ltd Net Asset Quality Index
Chengdu Easton Biopharmaceuticals Co Ltd net asset quality index. Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Net Asset Quality Index of 79.0% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.82 Billion minus total liabilities of CN¥802.42 Million yields net assets of CN¥3.02 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 688513 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
Net asset quality index of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the index stands at 79.0%, representing net assets of CN¥3.02 Billion against total assets of CN¥3.82 Billion CNY. See Chengdu Easton Biopharmaceuticals Co Ltd (688513) net assets for net asset value and shareholders' equity analysis.
Chengdu Easton Biopharmaceuticals Co Ltd Net Asset Quality Index by Year (2013–2025)
Chengdu Easton Biopharmaceuticals Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 688513 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 175.5% | CN¥6.66 Billion | CN¥3.80 Billion | CN¥-2.87 Billion | ▲ +96.1 pp |
| 2024 | 79.3% | CN¥2.70 Billion | CN¥3.40 Billion | CN¥702.21 Million | ▲ +1.6 pp |
| 2023 | 77.8% | CN¥2.60 Billion | CN¥3.35 Billion | CN¥743.33 Million | ▼ -3.2 pp |
| 2022 | 81.0% | CN¥2.44 Billion | CN¥3.02 Billion | CN¥573.08 Million | ▼ -1.6 pp |
| 2021 | 82.6% | CN¥2.29 Billion | CN¥2.78 Billion | CN¥483.60 Million | ▼ -0.2 pp |
| 2020 | 82.8% | CN¥2.10 Billion | CN¥2.53 Billion | CN¥435.61 Million | ▲ +12.1 pp |
| 2019 | 70.7% | CN¥697.44 Million | CN¥987.08 Million | CN¥289.64 Million | ▼ -3.1 pp |
| 2018 | 73.7% | CN¥582.19 Million | CN¥789.69 Million | CN¥207.50 Million | ▼ -1.5 pp |
| 2017 | 75.2% | CN¥445.28 Million | CN¥591.98 Million | CN¥146.70 Million | ▲ +0.3 pp |
| 2016 | 74.9% | CN¥389.79 Million | CN¥520.22 Million | CN¥130.43 Million | ▼ -11.1 pp |
| 2015 | 86.1% | CN¥268.21 Million | CN¥311.63 Million | CN¥43.42 Million | ▲ +14.3 pp |
| 2014 | 71.8% | CN¥203.25 Million | CN¥283.10 Million | CN¥79.85 Million | ▲ +5.6 pp |
| 2013 | 66.2% | CN¥168.62 Million | CN¥254.86 Million | CN¥86.24 Million | — |